International Stem Cell Corporation Announces Significant Progress Towards Creation of the First Bank of Immune-Matched Human Parthenogenetic Stem Cells
Published: Sep 28, 2010
OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com, announced today that its oocyte collection and activation protocol has received the approval of an Institutional Review Board (IRB). IRB review and approval is a Federal requirement for all studies enrolling human subjects, and ensures appropriate subject safety and monitoring to protect subjects from unnecessary medical risks. “Obtaining IRB approval for our oocyte collection and activation protocol is a major step forward towards the goal of building a viable bank of human parthenogenetic stem cells,” said Dr. Simon Craw, Vice President of ISCO.